The blood-brain barrier is the reason most gene therapies stop at the neck. A two-person team in Delaware thinks the answer has been circulating in our veins all along.
Crane Biosciences, founded in 2021 by Sujaan Das and Luca Bolondi, is developing a red blood cell-derived nanoparticle platform designed to carry RNA and gene therapy payloads into the brain [Entrepreneurs First]. The pitch is straightforward in concept and brutally hard in execution: take human red blood cells, the body's most abundant and immune-tolerated transport, and engineer them into nanoparticles (RBCNPs) that slip past the immune system and into tissues that synthetic carriers struggle to reach [Crunchbase]. The company has raised roughly $270,000 in pre-seed capital across two rounds, with backing from Entrepreneur First and Vento [CB Insights] [Crunchbase, June 2024].
The bet
Crane's wedge is delivery, not the payload. Most of the noise in RNA medicine over the last five years (Moderna, BioNTech, Alnylam) has focused on what the molecule does once it arrives. Crane is working on getting it there. Lipid nanoparticles, the workhorses of mRNA vaccines, accumulate heavily in the liver and provoke immune responses that limit repeat dosing. A red cell-derived carrier, in theory, sidesteps both problems: it is biologically native, and it can be engineered for tissue tropism. The company's stated focus is the brain, the organ where delivery has been the longest-standing failure mode of the gene therapy field [BIO]. Crane also says it pairs the wet-lab work with AI tooling for therapy design, though the specifics of that stack are not detailed in public materials [Crunchbase].
The business model is B2B. At this stage that almost certainly means a platform play: license or co-develop the delivery technology with pharma partners who own the disease assets, rather than carrying a single drug candidate through trials alone. It is the same path Alnylam, Moderna, and more recently companies like Generation Bio and Orna have walked, and it is capital-efficient relative to a vertically integrated biotech.
Why it could be big
The market shape is favorable. CNS-targeted gene therapy has been a graveyard for delivery science, which means a working RBCNP platform would not be competing for table scraps. It would be selling into a backlog of pharma programs, from Huntington's to ALS to rare pediatric encephalopathies, that are bottlenecked precisely on the problem Crane is trying to solve. The investor signal, while modest in dollar terms, is informed: Entrepreneur First has a long track record of backing technical co-founder pairs out of UK research institutions, and the firm typically writes its first check before there is a company at all [Entrepreneurs First]. Vento, an Italian early-stage fund, joined the cap table on the second round [Crunchbase, June 2024].
Crane is also listed as an exhibitor at the BIO International Convention 2026 [BIO], the kind of forum where platform biotechs find their first pharma conversations. For a company at this stage, that is a meaningful step out of the lab.
Pre-Seed Jan 2023 | 170000 | USD
Pre-Seed Jun 2024 | 125000 | USD
The team
Das and Bolondi both did doctoral work at the Francis Crick Institute as Marie Curie Fellows, a competitive EU research fellowship [Entrepreneur First]. Bolondi, listed as CTO, holds a second PhD in molecular biophysics across UCL and Imperial College London, and brings R&D experience in AI applied to microscopy along with three prior founder stints, one of which produced a biotech exit [Entrepreneur First]. Das is the biochemistry lead [Entrepreneur First]. The pair came together through Entrepreneur First's cohort model, which pairs technical founders and incubates the company from formation [Entrepreneurs First]. The company is incorporated in Delaware with research roots tied to Imperial College London [BIO].
What bears say, what bulls answer
The most credible concern is straightforward: red cell-derived delivery is an old idea that has frustrated multiple academic groups, and the brain is the hardest possible first indication. Erythrocyte-based carriers have been studied for decades without producing an approved CNS therapy, and competitors with vastly more capital, including Sangamo, Voyager Therapeutics, and Capsida, are pursuing AAV capsid engineering for the same target tissue. Bulls answer that the RBCNP approach is mechanistically distinct from AAV (no viral immunogenicity, potentially redoseable) and that Crane's bet is on engineered, not native, red cell biology [Crunchbase]. The Crick and Imperial pedigree of the founders, combined with Entrepreneur First's willingness to underwrite the formation risk, suggests the technical claim is taken seriously by people who can evaluate it. At $270,000 raised, the company has not yet had to defend the science to a lead biotech investor, and that conversation, when it comes, will be the real test.
What to watch
The near-term milestones are legible. First, a seed round. Pre-seed biotechs at this stage typically need to raise $3M to $8M to fund the in vivo work that converts a platform claim into a partnerable asset, and Crane's two pre-seed tranches in 2023 and 2024 suggest the team has been extending runway while generating data rather than racing to price. Second, a publication or preprint demonstrating brain biodistribution in a relevant animal model, the single piece of evidence that would meaningfully de-risk the platform thesis. Third, a named pharma research collaboration, even a small one, which is the standard early validation for a delivery-platform biotech. The BIO 2026 listing [BIO] hints the team is preparing to have those conversations.
The broader question for readers: if red blood cells turn out to be the right vehicle for getting RNA medicines into the brain, who captures the value, the platform companies like Crane, or the pharma partners who own the disease franchises?
Cash Quintero